Department of Clinical Biochemistry & Pharmacology, Odense University Hospital, Denmark; Clinical Pharmacology & Pharmacy, Department of Public Health, University of Southern Denmark, Odense, Denmark.
Clinical Pharmacology & Pharmacy, Department of Public Health, University of Southern Denmark, Odense, Denmark.
Eur J Obstet Gynecol Reprod Biol. 2019 Sep;240:293-299. doi: 10.1016/j.ejogrb.2019.07.023. Epub 2019 Jul 19.
Phthalates are chemical compounds present in a wide range of consumer products and are thought to be endocrine disruptors. Though not commonly known, phthalates are present in some medication with previous studies finding up to 50-fold higher urinary metabolite concentrations among exposed compared to the general population. Previous studies on environmental phthalate exposure and pregnancy outcomes have been contradictory and inconclusive and all previous studies have assessed phthalate exposure using biomarkers despite a known rapid metabolism of phthalates.
To determine whether phthalate exposure from pharmaceutical drugs have effects on preterm birth (PTB) and small for gestational age (SGA).
We conducted a nested case-control study among women in Denmark with a recorded singleton birth and included women who conceived between January 1st, 2004 and December 31st, 2015. To mitigate drug effect and confounding by underlying disease we included pregnancies exposed to selected study drugs, and compared pregnancies exposed to phthalate containing drugs to pregnancies exposed to phthalate free generic drugs. Using Danish health registries, we identified 30,899 singleton pregnancies exposed to study drugs available in both phthalate-containing and phthalate free versions. Using conditional logistic regression, we estimated associations between phthalate exposure and the risk of PTB and SGA. Birth weight according to gestational age was defined by INTERGROWTH-21st (SGA-I) and by Marsal's equation (SGA-M) for expected birthweight.
We included 1965 PTBs, 1315 SGA-Is, and 891 SGA-M cases, matched to 19,537, 12,008, and 7573 controls, respectively. Orthophthalate exposure during the third trimester was positively associated with PTB with a crude OR of 1.36 (95% CI: 1.06-1.76). The association was mainly due to diethyl phthalate. Exposure to phthalate polymers in third trimester was associated with a risk of PTB with crude ORs of 2.08 (CI: 1.16-3.71. No associations were found between orthophthalate or phthalate polymer exposure and SGA.
Exposure to some phthalate-containing pharmaceutical drugs during third trimester is associated with preterm birth.
邻苯二甲酸酯是存在于多种消费品中的化学化合物,被认为是内分泌干扰物。尽管人们并不常见,但一些药物中也含有邻苯二甲酸酯,先前的研究发现,暴露组的尿液代谢物浓度比一般人群高 50 倍。先前关于环境邻苯二甲酸酯暴露与妊娠结局的研究结果相互矛盾且不一致,并且所有先前的研究都使用生物标志物评估邻苯二甲酸酯暴露情况,尽管邻苯二甲酸酯的代谢速度很快。
确定来自药物的邻苯二甲酸酯暴露是否对早产 (PTB) 和胎儿生长受限 (SGA) 有影响。
我们在丹麦进行了一项嵌套病例对照研究,研究对象为记录有单胎分娩的女性,并纳入了 2004 年 1 月 1 日至 2015 年 12 月 31 日期间受孕的女性。为了减轻药物作用和基础疾病的混杂影响,我们纳入了暴露于选定研究药物的妊娠,并将暴露于含邻苯二甲酸酯药物的妊娠与暴露于无邻苯二甲酸酯的普通药物的妊娠进行比较。我们利用丹麦健康登记处,确定了 30899 例接受含邻苯二甲酸酯和无邻苯二甲酸酯版本的研究药物的单胎妊娠。使用条件逻辑回归,我们估计了邻苯二甲酸酯暴露与早产和胎儿生长受限风险之间的关联。根据 INTERGROWTH-21 标准(SGA-I)和 Marsal 方程(SGA-M)定义的按胎龄的出生体重,用于预测出生体重的 SGA。
我们纳入了 1965 例早产、1315 例 SGA-I 和 891 例 SGA-M 病例,分别匹配了 19537、12008 和 7573 例对照。第三孕期邻苯二甲酸酯暴露与早产呈正相关,未经校正的比值比 (OR) 为 1.36(95%CI:1.06-1.76)。这种关联主要归因于邻苯二甲酸二乙酯。第三孕期接触邻苯二甲酸酯聚合物与早产风险相关,未经校正的比值比 (OR) 为 2.08(CI:1.16-3.71)。邻苯二甲酸酯或邻苯二甲酸酯聚合物暴露与胎儿生长受限均无关联。
在妊娠晚期接触某些含邻苯二甲酸酯的药物与早产有关。